Daiwa Capital Markets America’s Regeneron Pharmaceuticals REGN Stock Holding History

Daiwa Capital Markets America’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	$606K	Buy	+2,200	New	+$633K	0.01%	352

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Daiwa Capital Markets America's REGN Position: Q4 2013 in Review

Daiwa Capital Markets America opened a new position in Regeneron Pharmaceuticals (REGN) in Q4 2013: 2,200 shares worth $606K. The stake represents 0.01% of the portfolio and ranks #352 among its holdings.

438 funds tracked by Wall St. Rank hold REGN as of Q4 2013.

Daiwa Capital Markets America held 2,200 shares of Regeneron Pharmaceuticals worth $606K as of Q4 2013.
Regeneron Pharmaceuticals was a new Daiwa Capital Markets America position in Q4 2013.
Regeneron Pharmaceuticals made up 0.01% of Daiwa Capital Markets America's portfolio in Q4 2013, its #352 holding.
438 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2013.

Based on Daiwa Capital Markets America's 13F filing for Q4 2013, filed 13 Feb 2014.